EWA
HOWL icon

EverSource Wealth Advisors’s Werewolf Therapeutics HOWL Stock Holding History

EverSource Wealth Advisors’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-35
Closed -$69 – 4335
2025
Q3 		$69 Sell
35
-132
-79% -$181 ﹤0.01% 4228
2025
Q2 		$182 Buy
167
+132
+377% +$136 ﹤0.01% 4068
2025
Q1 		$34 Buy
35
+2
+6% +$3 ﹤0.01% 3935
2024
Q4 		$49 Buy
+33
New +$67 ﹤0.01% 3640

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EverSource Wealth Advisors's HOWL Position: Q4 2025 in Review

EverSource Wealth Advisors sold out of Werewolf Therapeutics (HOWL) in Q4 2025, closing a stake of 35 shares — an estimated $69 sold.

EverSource Wealth Advisors first reported a position in HOWL in Q4 2024 and held it in 4 quarters. The position peaked at $182 in Q2 2025. 51 funds tracked by Wall St. Rank hold HOWL as of Q4 2025.

  • EverSource Wealth Advisors reported no remaining Werewolf Therapeutics position as of Q4 2025 after selling out during the quarter.
  • EverSource Wealth Advisors sold 35 Werewolf Therapeutics shares in Q4 2025, an estimated $69.
  • EverSource Wealth Advisors first reported a position in Werewolf Therapeutics in Q4 2024 and held it in 4 quarters.
  • EverSource Wealth Advisors's Werewolf Therapeutics position peaked at $182 in Q2 2025.
  • 51 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q4 2025.

Based on EverSource Wealth Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.